De Maria E, Giacopelli D, Borghi A, Modonesi L, Cappelli S. Antitachycardia pacing programming in implantable cardioverter defibrillator: A systematic review. World J Cardiol 2017; 9(5): 429-436 [PMID: 28603590 DOI: 10.4330/wjc.v9.i5.429]
Corresponding Author of This Article
Elia De Maria, MD, PhD, Chief of Arrhythmology Lab, Cardiology Unit, Ramazzini Hospital, Via Molinari 1, 41012 Carpi (Modena), Italy. e.demaria@inwind.it
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Elia De Maria, Ambra Borghi, Letizia Modonesi, Stefano Cappelli, Cardiology Unit, Ramazzini Hospital, 41012 Carpi (Modena), Italy
Daniele Giacopelli, Biotronik Italia, Dipartimento Clinico, 20090 Vimodrone, Italy
Author contributions: De Maria E and Giacopelli D contributed to concept/design, data analysis/interpretation, drafting the article, critical revision, approval; Borghi A, Modonesi L and Cappelli S contributed to drafting the article, critical revision, approval.
Conflict-of-interest statement: Daniele Giacopelli is a Biotronik employee. The other authors report no relationships that could be construed as a conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Elia De Maria, MD, PhD, Chief of Arrhythmology Lab, Cardiology Unit, Ramazzini Hospital, Via Molinari 1, 41012 Carpi (Modena), Italy. e.demaria@inwind.it
Telephone: +39-05-9659320 Fax: +39-05-9659387
Received: November 14, 2016 Peer-review started: November 14, 2016 First decision: February 15, 2017 Revised: February 24, 2017 Accepted: March 12, 2017 Article in press: March 13, 2017 Published online: May 26, 2017 Processing time: 187 Days and 7.8 Hours
Core Tip
Core tip: Antitachycardia pacing (ATP) has a great importance in the treatment of ventricular arrhythmias, whether slow or fast. It reduces the number of unnecessary shocks and it improves both patient’s quality of life and device longevity. Beyond ATP use, excellent clinical results were obtained with programming standardization following these principles: Extended detection in ventricular fibrillation (VF) zone; supraventricular discrimination criteria up to 200 bpm; first shock in VF zone at the maximum energy in order to reduce the risk of multiple shocks. The MADIT-RIT trial and some registries have also recently demonstrated that programming with a widespread use of ATP, higher cut-off rates or delayed intervention reduces the number of inappropriate therapies and improves the survival of patients during medium term follow-up.
